Shirley Chen
Stock Analyst at Barclays
(2.99)
# 2,646
Out of 4,476 analysts
36
Total ratings
57.7%
Success rate
6.8%
Average return
Main Sectors:
Stocks Rated by Shirley Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €22.00 | $26.90 | -18.22% | 4 | May 7, 2026 | |
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 350.00 → kr 470.00 | $479.00 | -1.88% | 5 | Feb 24, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €105.00 | $75.81 | +38.50% | 1 | Dec 15, 2025 | |
| SWX: NOVN Novartis AG | Maintained: Sell | CHF 90.00 | $127.92 | -29.64% | 6 | Nov 21, 2025 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 1,875 → kr 2,000 | $1,861.29 | +7.45% | 9 | Nov 10, 2025 | |
| LON: GSK GSK plc | Maintained: Hold | 1,450p | $2,015.00 | -28.04% | 6 | Oct 31, 2025 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 14,000p | $14,456.00 | -3.15% | 5 | Oct 21, 2025 |
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: €22.00
Current: $26.90
Upside: -18.22%
Swedish Orphan Biovitrum AB (publ)
Feb 24, 2026
Maintained: Buy
Price Target: kr 350.00 → kr 470.00
Current: $479.00
Upside: -1.88%
Sanofi
Dec 15, 2025
Maintained: Buy
Price Target: €105.00
Current: $75.81
Upside: +38.50%
Novartis AG
Nov 21, 2025
Maintained: Sell
Price Target: CHF 90.00
Current: $127.92
Upside: -29.64%
Genmab A/S
Nov 10, 2025
Maintained: Buy
Price Target: kr 1,875 → kr 2,000
Current: $1,861.29
Upside: +7.45%
GSK plc
Oct 31, 2025
Maintained: Hold
Price Target: 1,450p
Current: $2,015.00
Upside: -28.04%
AstraZeneca PLC
Oct 21, 2025
Maintained: Buy
Price Target: 14,000p
Current: $14,456.00
Upside: -3.15%